CN105101999B - 用在病毒性疾病的治疗中的mek抑制剂 - Google Patents

用在病毒性疾病的治疗中的mek抑制剂 Download PDF

Info

Publication number
CN105101999B
CN105101999B CN201380064116.5A CN201380064116A CN105101999B CN 105101999 B CN105101999 B CN 105101999B CN 201380064116 A CN201380064116 A CN 201380064116A CN 105101999 B CN105101999 B CN 105101999B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
oseltamivir
inhibitor
mek
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380064116.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105101999A (zh
Inventor
S·普莱施卡
O·普兰兹
S·路德维格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Home Therapy Co Ltd
Original Assignee
Westfaelische Wilhelms Universitaet Muenster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Westfaelische Wilhelms Universitaet Muenster filed Critical Westfaelische Wilhelms Universitaet Muenster
Priority to CN201810617076.7A priority Critical patent/CN109276716B/zh
Publication of CN105101999A publication Critical patent/CN105101999A/zh
Application granted granted Critical
Publication of CN105101999B publication Critical patent/CN105101999B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380064116.5A 2012-10-08 2013-10-08 用在病毒性疾病的治疗中的mek抑制剂 Active CN105101999B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810617076.7A CN109276716B (zh) 2012-10-08 2013-10-08 用在病毒性疾病的治疗中的mek抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261711136P 2012-10-08 2012-10-08
US61/711,136 2012-10-08
PCT/EP2013/070917 WO2014056894A1 (en) 2012-10-08 2013-10-08 Mek inhibitors in the treatment of virus diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810617076.7A Division CN109276716B (zh) 2012-10-08 2013-10-08 用在病毒性疾病的治疗中的mek抑制剂

Publications (2)

Publication Number Publication Date
CN105101999A CN105101999A (zh) 2015-11-25
CN105101999B true CN105101999B (zh) 2018-07-17

Family

ID=49552318

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380064116.5A Active CN105101999B (zh) 2012-10-08 2013-10-08 用在病毒性疾病的治疗中的mek抑制剂
CN201810617076.7A Active CN109276716B (zh) 2012-10-08 2013-10-08 用在病毒性疾病的治疗中的mek抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810617076.7A Active CN109276716B (zh) 2012-10-08 2013-10-08 用在病毒性疾病的治疗中的mek抑制剂

Country Status (10)

Country Link
US (2) US9566281B2 (https=)
EP (1) EP2903649A1 (https=)
JP (2) JP6294889B2 (https=)
KR (1) KR102174576B1 (https=)
CN (2) CN105101999B (https=)
AU (1) AU2013328824B2 (https=)
BR (1) BR112015007616B1 (https=)
CA (1) CA2886138C (https=)
EA (1) EA028605B1 (https=)
WO (1) WO2014056894A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2014056894A1 (en) * 2012-10-08 2014-04-17 Westfaelische Wilhelms-Universitaet Muenster Mek inhibitors in the treatment of virus diseases
CN113398271A (zh) 2014-05-16 2021-09-17 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略
JPWO2018030534A1 (ja) * 2016-08-10 2019-06-13 国立研究開発法人理化学研究所 Ｂ型肝炎治療用組成物、及びｂ型肝炎ウイルスの複製活性の評価方法
WO2018095403A1 (zh) * 2016-11-25 2018-05-31 江苏恒瑞医药股份有限公司 一种吡啶酮类衍生物药物组合物及其制备方法
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
EP3973960B1 (en) 2017-10-17 2025-09-03 Atriva Therapeutics GmbH Novel mek-inhibitor for the treatment of viral and bacterial infections
US20190298669A1 (en) * 2018-03-29 2019-10-03 Atriva Therapeutics Gmbh Ci-1040 for the treatment of viral diseases
US12599591B2 (en) * 2018-10-03 2026-04-14 Jyväskylän Yliopisto Vemurafenib and salts thereof for use in the treatment of enteroviral infections
CN109765324B (zh) * 2018-11-27 2021-03-30 苏州科技大学 一种mek1蛋白潜在抑制剂的筛选方法
JP2022526199A (ja) 2019-03-19 2022-05-23 アトリバ セラピューティクス ゲーエムベーハー ウイルス疾患の治療におけるｒｓｋ阻害剤
LU101183B1 (en) 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
KR20220074869A (ko) 2019-08-27 2022-06-03 아트리바 테라퓨틱스 게엠베하 Mek 억제제와 캡-의존성 엔도뉴클레아제 억제제의 조합
JP7802365B2 (ja) * 2019-10-08 2026-01-20 アトリバ セラピューティクス ゲーエムベーハー ハンタウイルス感染症の処置のためのｍｅｋ阻害剤
WO2021214296A1 (en) * 2020-04-24 2021-10-28 Johann Wolfgang Goethe-Universität Frankfurt am Main Treatment of corona virus infections
CN111529532A (zh) * 2020-05-05 2020-08-14 华中科技大学同济医学院附属协和医院 曲美替尼在制备治疗肺部炎症性疾病药物及促进Tfh细胞分化药物中的应用
CN111494620A (zh) * 2020-05-05 2020-08-07 华中科技大学同济医学院附属协和医院 曲美替尼在制备疫苗中的应用
CN112137994B (zh) * 2020-09-15 2022-10-14 中山大学 小分子化合物在制备抗丝状病毒药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1434711A (zh) * 2000-04-07 2003-08-06 麦丁诺瓦学术研究医疗革新有限责任公司 起Raf/MEK/ERK信号级联的级联抑制剂作用的物质在制备治疗DNA和RNA病毒感染的药物中的应用
CN102036658A (zh) * 2008-05-23 2011-04-27 香港大学 治疗流感的联合疗法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05509327A (ja) 1990-07-30 1993-12-22 プロシオン・フアーマシユーテイカルズ・インコーポレーテツド 抗炎症および抗ウイルス活性を有する蛋白質キナーゼｃモジュレーター
US5866601A (en) 1995-02-27 1999-02-02 Gilead Sciences, Inc. Carbocyclic compounds
US5763483A (en) 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
WO2000040237A1 (en) * 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
DE10138912A1 (de) 2001-08-08 2003-02-27 Medinnova Ges Med Innovationen Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
WO2014056894A1 (en) * 2012-10-08 2014-04-17 Westfaelische Wilhelms-Universitaet Muenster Mek inhibitors in the treatment of virus diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1434711A (zh) * 2000-04-07 2003-08-06 麦丁诺瓦学术研究医疗革新有限责任公司 起Raf/MEK/ERK信号级联的级联抑制剂作用的物质在制备治疗DNA和RNA病毒感染的药物中的应用
CN102036658A (zh) * 2008-05-23 2011-04-27 香港大学 治疗流感的联合疗法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo;Karoline Droebner等;《Antiviral Research》;20110811;第92卷;第195–203页 *
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886);J Meng等;《Cancer Biology & Therapy》;20091101;第8卷(第21期);第2073-2080页 *
MEK inhibitors: a patent review 2008-2010;John I Trujillo;《Expert Opin. Ther. Patents》;20111231;第21卷(第7期);第1045-1069页 *
Stephan Ludwig等.MEK inhibition impairs in£uenza B virus propagation without emergence of resistant variants.《FEBS Letters》.2004,第561卷第37-43页. *
Strategies of Development of Antiviral Agents Directed Against Influenza Virus Replication;Hsing-Pang Hsieh等;《Current Pharmaceutical Design》;20071231;第13卷(第34期);第3531-3542页 *
Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy;Stephan Ludwig;《Journal of Antimicrobial Chemotherapy》;20090506;第1-4页 *
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner;EW Joseph等;《Proceedings of the National Academy of Sciences》;20100817;第107卷(第33期);第14903-14908页 *
U0126 and PD98059, Specific Inhibitors of MEK, Accelerate Differentiation of RAW264.7 Cells into Osteoclast-like Cells;H Hotokezaka等;《Journal of Biological Chemistry》;20020916;第277卷(第49期);第47366-47372页 *
神经氨酸苷酶抑制剂研究进展;王明涛等;《天津理工学院院报》;20010630;第17卷(第2期);第21-24页 *

Also Published As

Publication number Publication date
CN109276716B (zh) 2021-06-08
CN109276716A (zh) 2019-01-29
KR102174576B1 (ko) 2020-11-06
BR112015007616A2 (pt) 2017-08-08
AU2013328824A1 (en) 2015-04-30
JP2018118971A (ja) 2018-08-02
CA2886138C (en) 2021-10-12
BR112015007616B1 (pt) 2022-08-09
JP2015534562A (ja) 2015-12-03
CA2886138A1 (en) 2014-04-17
EA201590703A1 (ru) 2015-07-30
WO2014056894A1 (en) 2014-04-17
US9566281B2 (en) 2017-02-14
US20150224103A1 (en) 2015-08-13
US20170209450A1 (en) 2017-07-27
AU2013328824B2 (en) 2018-04-05
KR20150097464A (ko) 2015-08-26
EA028605B1 (ru) 2017-12-29
CN105101999A (zh) 2015-11-25
EP2903649A1 (en) 2015-08-12
JP6294889B2 (ja) 2018-03-14

Similar Documents

Publication Publication Date Title
CN105101999B (zh) 用在病毒性疾病的治疗中的mek抑制剂
WO2021214033A1 (en) Vidofludimus for use in the treatment or prevention of viral diseases
EP2694046A1 (en) Methods and pharmaceutical compositions for inhibiting influenza viruses replication
JP2023519277A (ja) 伝染性ｒｎａウイルス感染症の予防又は治療するための医薬組成物
WO2020241759A1 (ja) インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤
WO2013131496A1 (zh) 治疗病毒疾病的成分和方法
US20220370384A1 (en) Combinations of mek inhibitors with cap-dependent endonuclease inhibitors
KR102890706B1 (ko) 인플루엔자 바이러스 복제 억제제의 조합물
US20190298669A1 (en) Ci-1040 for the treatment of viral diseases
HK40003862B (zh) 用在病毒性疾病的治疗中的mek抑制剂
HK40003862A (en) Mek inhibitors in the treatment of virus diseases
CN104857007A (zh) 一种流感病毒神经氨酸酶的新型抑制剂及其用途
JP7727641B2 (ja) ジルチアゼムとウイルスポリメラーゼ阻害薬との組合せ
CN121466087A (zh) Pha-767491在制备防治h1n1亚型猪流感药物中的应用
CN121445739A (zh) Pha-767491作为h3n2亚型猪流感病毒复制抑制剂的应用
AU2018202283A1 (en) Ci-1040 for the treatment of viral diseases
HK40049091A (en) Combinations of inhibitors of influenza virus replication
CA2999670A1 (en) Ci-1040 for the treatment of viral diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20170503

Address after: The German city of tvbingen

Applicant after: Home therapy Company Limited

Address before: Giessen

Applicant before: S. Pleschka

Applicant before: O*Plains

Applicant before: S*Ludwig

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant